Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2017—Asuragen entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics. Asuragen will leverage its AmplideX PCR/CE product technologies to develop diagnostic kits for the 3500 Dx Series Genetic Analyzer CS2 instrument.
May 2017—Nova Biomedical received the CE mark for its Allegro, a capillary blood analyzer for point-of-care testing in primary care settings. Allegro and its StatStrip A companion meter provide 14 clinically important tests to monitor glycemic control, assess cardiac risk with a full lipids panel, and assess kidney function. Results are ready during the patient visit.
April 2017—Proscia, a data solutions provider for digital pathology founded in 2014 by a team from Johns Hopkins, the Moffitt Cancer Center, and the University of Pittsburgh, and Asan Medical Center, a South Korean clinical and biomedical research institute, announced a partnership focused on developing tools that enable predictive medicine in the fight against cancer.
April 2017—ViroStat has introduced three Monotope monoclonal antibodies that are specific to Chlamydia pneumonia and do not cross-react with the related Chlamydia trachomatis and Chlamydia psittaci. They function in ELISA and IFA and are candidates for rapid test applications.
April 2017—Bio SB announced it now offers 25 monoclonal antibodies for IVD applications. Among the new products is a line of reagents for mesothelioma diagnosis, including BAP1, mesothelial cell HBME 1, and caveolin 1.
April 2017—The Diesse Mini-Cube automated sed-rate instrument is now compatible with 500 µL patient samples in BD Microtainer tubes with K2 EDTA. The Mini-Cube also analyzes standard 13 × 75 mm K2 EDTA tubes with a patient sample fill volume range of 2.0 mL to 4.0 mL.
April 2017—Quest Diagnostics launched a test service that aims to help physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus. The HBsAg qualitative test is used to aid in diagnosis of patients with HBV.
April 2017—The new IsoFreeze PCR Rack from Sarstedt aims to ensure consistently cooled PCR samples. Premature warming of PCR samples during preparation can result in nonspecific PCR products.
April 2017—SeraCare Life Sciences launched its Seraseq Fusion RNA Mix v2 and Seraseq FFPE Fusion RNA Reference Material v2. The highly multiplexed mixes include 15 clinically actionable fusion RNA partners. Two formats are offered—purified nucleic acid (Fusion RNA Mix) and formalin-fixed, paraffin-embedded tissue slices (FFPE Fusion RNA Reference material).
April 2017—MedTest announced the commercial launch of urine drugs of abuse screening reagents on the Mindray BA-800M chemistry analyzer for use in clinical laboratories in the United States.
